Core Viewpoint - Arrowhead Pharmaceuticals has initiated dosing of the first subjects in a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference therapeutic aimed at treating tauopathies, including Alzheimer's disease, which is a leading cause of dementia [1] Group 1 - The clinical trial for ARO-MAPT represents a significant step in the development of potential treatments for Alzheimer's disease, a progressive neurodegenerative condition [1] - Alzheimer's disease is characterized by cognitive and functional decline, affecting a substantial number of individuals globally [1]